HYDERABAD: Pharma major Dr Reddy’s Laboratories is foraying into the trade generics business in the Indian market with the rollout of a new dedicated division — RGenX. The company will be selling unbranded generic medicines that are copycat versions of innovator drugs which have gone off-patent under this new division.
The Hyderabad-based company said it will roll out its trade generics business across cities, towns and rural areas across the country by working closely with channel partners to ensure availability of its products.
The focus, to start with, will be on acute segment products such as respiratory and anti-infectives. The business will work on a model driven by channel partners wherein the retailer will push the medicines instead of a prescription-driven model.
The move is part of the Hyderabad-based company’s focus on expanding its reach in the Indian market as part of its goal to reach over 1.5 billion patients by 2030 and providing affordable quality medicines to patients.
Pointing out that India was a key focus market for Dr Reddy’s Labs, its CEO for India & Emerging Markets MV Ramana termed the move as a continuation of its effort to build a well-rounded business in India while strengthening its branded generics business by growing brands, new product launches, productivity enhancement through digital and analytics, and select strategic acquisitions.
“We are exploring strategic collaborations in India, and investing in innovative healthcare spaces we see as future growth drivers. This foray will add to our reach and depth by making high-quality medicines accessible to more patients around the country,” he added.
The Hyderabad-based company said it will roll out its trade generics business across cities, towns and rural areas across the country by working closely with channel partners to ensure availability of its products.
The focus, to start with, will be on acute segment products such as respiratory and anti-infectives. The business will work on a model driven by channel partners wherein the retailer will push the medicines instead of a prescription-driven model.
The move is part of the Hyderabad-based company’s focus on expanding its reach in the Indian market as part of its goal to reach over 1.5 billion patients by 2030 and providing affordable quality medicines to patients.
Pointing out that India was a key focus market for Dr Reddy’s Labs, its CEO for India & Emerging Markets MV Ramana termed the move as a continuation of its effort to build a well-rounded business in India while strengthening its branded generics business by growing brands, new product launches, productivity enhancement through digital and analytics, and select strategic acquisitions.
“We are exploring strategic collaborations in India, and investing in innovative healthcare spaces we see as future growth drivers. This foray will add to our reach and depth by making high-quality medicines accessible to more patients around the country,” he added.
